… different oral anticoagulants across the range of kidney function. The study found that,
relative to warfarin, NOACs are used progressively less commonly as patients’ kidney function …

… (DOACs) in atrial fibrillation (AF) patients with renal impairment are … oral anticoagulants
(OACs) in AF patients with renal impairment, including advanced chronic kidney disease (CKD) …

… the safety and efficacy of any new oral anticoagulant compared to oral anticoagulation
with … AF, (2) evaluated renal function at baseline, and (3) reported outcomes in relation to …

… The direct oral anticoagulants (DOAC) inhibiting factor Xa or thrombin … kidney disease,
caution is warranted, as DOACs can accumulate as they are partly eliminated by the kidneys. Thus…

… discussed extensively the clinical utility of oral anticoagulants in CKD ( 4 ). This review article
will focus on the pharmacology of commonly used oral anticoagulants that are important in …

… and safety, especially in patients with impaired renal function (… controlled trials with
anticoagulants, making evidence-based … on the renal aspects of the new oral anticoagulant drugs …

… to investigate whether oral anticoagulants can provide efficacy and safety profiles better than
no anticoagulant in patients with stages 4 or 5 chronic kidney disease and atrial fibrillation. …

… the safety and efficacy of DOACs in advanced kidney disease. Direct oral anticoagulants, while
… by the FDA for use in patients with chronic kidney disease (CKD). The FDA has approved …

… treatment effects of NOACs according to renal function, we performed a meta‐analysis in
order to (i) assess the safety of NOACs in patients with moderate or severe renal failure, and (ii) …

… anticoagulants. This study aimed to compare the two methods of assessment of renal function
… either the selection of patients for the new oral anticoagulants or the dose of dabigatran or …